Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Donor and recipient age-related differences in immunological reconstitution affect development of chronic graft-versus-host disease

View Full Paper
Ask AI
Bookmark
Share

Authors

TNTakaya Nishio

Discussion

Loading...

Member takes

Overview

Observational study shows immune function reconstitution varies with age in allogeneic hematopoietic cell transplantation, highlighting potential impacts on chronic gvhd.

Key Points

  • This research aims to investigate the impact of donor and recipient age on immunological reconstitution and its influence on chronic graft-versus-host disease.
  • Evaluated 81 cases of allogeneic hematopoietic cell transplantation (HCT) from 2008 to 2023
  • Classified patients into age groups and donor sources (umbilical cord blood vs. bone marrow/peripheral blood)
  • Analyzed CD4/CD8 T cells, Treg cells, and cytokine production using flow cytometry and assays.
  • Younger patients showed improved T cell reconstitution and higher Treg cell expansion post-transplant
  • Cytokine production levels differed, with younger patients demonstrating stronger responses over time
  • No significant immunological recovery differences were noted in older patients regardless of donor source.

Cite This Study

Takaya Nishio (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236def6https://doi.org/10.1182/blood-2025-4230
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of age on graft-versus-host disease and overall survival in pediatric hematopoietic cell transplant recipients2025 · 3 citations
  2. 2Impact of donor age on transplant outcomes in unrelated allogeneic hematopoietic stem cell transplantation using post-transplant cyclophosphamide-based gvhd prophylaxis2025
  3. 3Ageing of long-term allogeneic hematopoietic cells recipients compared to their donors2022
  4. 4Differentiating donor age on AML patient outcomes in the post-transplant cyclophosphamide contemporary era.2026
  5. 5Can immune reconstitution parameters be highlighted for chronic graft versus host disease in children one month after HSCT?2024